Clinical trials: HNSCC,Larynx, Pharynx and Oral Cavity
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
This phase II trial studies the effect of cemiplimab in combination with low-dose paclitaxel and carboplatin in treating patients with squamous cell carcinoma of the head and neck that has come back (recurrent) or spread to other…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT04862650
- Testing
- Carboplatin, Cemiplimab, Paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Marcelo Bonomi
Head and Neck Cancer, Squamous Cell Carcinoma
Pembrolizumab in Combination With CRT for LA-SCCHN
This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT02586207
- Testing
- pembrolizumab (MK-3475), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanford Health
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004094
- Testing
- carboplatin, fluorouracil, hydroxyurea
- Where
- 4 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00833261
- Testing
- cetuximab, cisplatin, intensity-modulated radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Texas Southwestern Medical Center
Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
This phase I trial studies the side effects of image-guided hyper-fractioned proton therapy in treating patients with head and neck cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed…
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04870840
- Testing
- Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma
Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
This randomized phase I/II trial studies the side effects and best way to give lyophilized black raspberries in preventing oral cancer in high-risk patients previously diagnosed with stage I-IV or in situ head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage 0 Hypopharyngeal Cancer, Stage 0 Laryngeal Cancer
- Trial name
- NCT01469429
- Testing
- laboratory biomarker analysis, questionnaire administration, chemoprevention
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma
- Trial name
- NCT06980038
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Oropharyngeal Carcinoma
Thermotherapy for Head and Neck Cancer Patients
This phase I, single-center study evaluates the safety, tolerability, and recommended phase II dose (RP2D) of mild hyperthermia (thermotherapy) when added to standard-of-care treatment in patients with locally advanced head and…
- Conditions
- Head and Neck Cancer, Oropharyngeal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma
- Trial name
- TANCAP-I (NCT07690618)
- Testing
- Thermotherapy, Radiotherapy, Concurrent chemoradiation
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
Head and Neck Cancer
S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat
RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00017173
- Testing
- Ad5CMV-p53 gene, cisplatin, conventional surgery
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- SWOG Cancer Research Network
Dysphagia, Head and Neck Cancer
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
- Trial name
- NCT00503776
- Testing
- exercise intervention, amifostine trihydrate, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
This phase I trial is to find out the possible side effects of pembrolizumab and radiation therapy before and during surgery in treating patients with head and neck squamous cell cancer that remains despite treatment (persistent)…
- Conditions
- Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04754321
- Testing
- External Beam Radiation Therapy, Intraoperative Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
This study is exploring the use of Panitumumab in Head and Neck Cancer. Panitumumab is an approved drug named Vectibix and is used as an anti-cancer agent in other cancers such as colorectal cancer.
- Conditions
- HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma
- Trial name
- NCT06819228
- Testing
- Panitumumab IRDye 800
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
This phase II trial tests how well lovastatin and pembrolizumab work in treating patients with head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06636734
- Testing
- Biospecimen Collection, Computed Tomography, Lovastatin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Emory University
Head and Neck Squamous Cell Carcinoma
2B or Not 2B? Shoulder Function After Level 2B Neck Dissection: A Randomized Controlled Study
Many types of head and neck cancers will have local spread to the neck. As such selective neck dissection is performed as part of the treatment. The neck is divided into various levels.
- Trial name
- 2BN2B (NCT00765791)
- Testing
- Selective Neck Dissection Excluding Level 2B, Selective Neck Dissection Including Level 2B
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
The study is an open-label phase I/II clinical trial. The study will enroll patients to receive neoadjuvant SBRT plus 1 or 2 doses of neoadjuvant pembrolizumab with concurrent ficerafusp alfa (4 doses) prior to definitive…
- Trial name
- NCT07552558
- Testing
- Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
The purpose of this study is to test the safety and tolerability of chemotherapy and radiation in combination with the investigational study drugs zimberelimab (AB122) and etrumadenant (AB928) in subjects with a locally advances…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oral Cavity Cancer
- Trial name
- PANTHEoN (NCT04892875)
- Testing
- Zimberelimab, Etrumadenant, Cisplatin
- Sponsor
- Jennifer Choe
Head and Neck Cancer
PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy
RATIONALE: Imaging procedures, such as PET scans, may determine the extent of cancer and help doctors plan radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- TEPORL (NCT00809016)
- Testing
- 3-dimensional conformal radiation therapy, fludeoxyglucose F 18, intensity-modulated radiation therapy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Oscar Lambret
Head and Neck Cancer
Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00530088
- Testing
- porfimer sodium, Photdynamic Therapy (PDT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma of Unknown Primary, Head and Neck Cancer
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and…
- Conditions
- Carcinoma of Unknown Primary, Head and Neck Cancer, Non-melanomatous Skin Cancer
- Trial name
- NCT00006361
- Testing
- semaxanib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center